A study in Cancer Cell International finds higher levels of vitamin B1 and vitamin B5 in the serum of breast cancer patients and patients with benign breast diseases along with a positive correlation of vitamin B1 with breast cancer risk.
At present, most of the existing studies on the relationship between vitamins and breast cancer risk are conducted in European populations, while there are few studies in Asian populations, and the conclusions of these studies are not consistent.
The subjects have been informed of the contents of the test in the institute, and all subjects have volunteered to participate in the research measurement and signed a written informed consent form.From September 2020 to December 2020, 520 subjects who were treated at Yunnan Provincial Tumor Hospital from 8 am to the Department of Breast Surgery of Yunnan Provincial Tumor Hospital to collect peripheral venous blood before breakfast on an empty stomach to assess serum vitamin levels.
All breast cancer patients’ pathological diagnosis, immunohistochemical results, and Fish gene test were obtained by the Department of Pathology, Yunnan Cancer Hospital. The chemotherapy patients in the breast cancer group were all undergoing chemotherapy in the Department of Breast Surgery of Yunnan Cancer Hospital and they were all undergoing chemotherapy.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Variability Among Breast Cancer Risk Classification Models When Applied at the Level of the Individual Woman - Journal of General Internal MedicineBackground Breast cancer risk models guide screening and chemoprevention decisions, but the extent and effect of variability among models, particularly at the individual level, is uncertain. Objective To quantify the accuracy and disagreement between commonly used risk models in categorizing individual women as average vs. high risk for developing invasive breast cancer. Design Comparison of three risk prediction models: Breast Cancer Risk Assessment Tool (BCRAT), Breast Cancer Surveillance Consortium (BCSC) model, and International Breast Intervention Study (IBIS) model. Subjects Women 40 to 74 years of age presenting for screening mammography at a multisite health system between 2011 and 2015, with 5-year follow-up for cancer outcome. Main Measures Comparison of model discrimination and calibration at the population level and inter-model agreement for 5-year breast cancer risk at the individual level using two cutoffs (≥ 1.67% and ≥ 3.0%). Key Results A total of 31,115 women were included. When using the ≥ 1.67% threshold, more than 21% of women were classified as high risk for developing breast cancer in the next 5 years by one model, but average risk by another model. When using the ≥ 3.0% threshold, more than 5% of women had disagreements in risk severity between models. Almost half of the women (46.6%) were classified as high risk by at least one of the three models (e.g., if all three models were applied) for the threshold of ≥ 1.67%, and 11.1% were classified as high risk for ≥ 3.0%. All three models had similar accuracy at the population level. Conclusions Breast cancer risk estimates for individual women vary substantially, depending on which risk assessment model is used. The choice of cutoff used to define high risk can lead to adverse effects for screening, preventive care, and quality of life for misidentified individuals. Clinicians need to be aware of the high false-positive and false-negative rates and variation between models when talking with pati
続きを読む »
Combination IFNβ and membrane-stable CD40L maximize tumor dendritic cell activation and lymph node trafficking to elicit systemic T-cell immunityAbstract. Oncolytic viral therapies induce direct killing of tumor cells and activation of conventional dendritic cells (cDCs); however, cDC activation has not been optimized with current therapies. We evaluated adenoviral delivery of engineered membrane-stable CD40L (MEM40) and IFNβ to locally activate cDCs in mouse tumor models. Combined tumor MEM40 and IFNβ expression induced the highest cDC activation coupled with increased lymph node migration, increased systemic antitumor CD8+ T-cell responses, and regression of established tumors in a cDC1-dependent manner. MEM40+IFNβ combined with checkpoint inhibitors led to effective control of distant tumors and lung metastases. An oncolytic adenovirus (MEM-288) expressing MEM40+IFNβ in phase 1 clinical testing induced cancer cell loss concomitant with enhanced T-cell infiltration and increased systemic presence of tumor T-cell clonotypes in NSCLC patients. This approach to simultaneously target two major DC-activating pathways has potential to significantly impact the solid tumor immunotherapy landscape.
続きを読む »
Woman rescued after being 'held in makeshift cell' for 20 yearsA woman has been freed after being held captive in a 'makeshift cell' in her mother's home for 20 years.
続きを読む »
Boston-Based Vertex Aims to Tackle Sickle Cell Disease, Inspire StudentsResearchers at a Boston pharmaceutical company hope to make sickle cell disease — a blood disorder that disproportionately affects Black people — more manageable for patients. Vertex Pharmaceuticals says it is trying to use gene editing to restore impacted blood cells and reduce symptoms. And the scientists working on the solution hope their actions will help inspire a new generation…
続きを読む »
'Britain's FBI' appeals to find UK's seven most wanted fugitives in international huntThe National Crime Agency has renewed an appeal to track down some of the UK\u2019s most wanted fugitives.
続きを読む »